<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/css" href="https://imcjms.com/assets/rss.css" ?><rss version="2.0">
<channel>
    <title>IMC Journal of Medical Science</title>
    <link>https://imcjms.com</link>
    <description>Ibrahim Medical College Journal of Medical Science</description>

                        <item>
                <title><![CDATA[Dengue in Bangladesh and neighboring countries: an
overview of epidemiology, transmission, control, and prevention]]></title>

                                    <author><![CDATA[M. S. Zaman*]]></author>
                                    <author><![CDATA[Amal K. Mitra]]></author>
                
                <link data-url="https://imcjms.com/registration/journal_full_text/511">
    https://imcjms.com/registration/journal_full_text/511
</link>
                <pubDate>Sat, 27 Jan 2024 09:51:23 +0000</pubDate>
                <category><![CDATA[Review]]></category>
                <comments><![CDATA[IMC J Med Sci. 2024; 18(1):012]]></comments>
                <description>Abstract
Background and Objectives: Dengue fever,
caused by four serotypes of the dengue virus (DENV), is a global health threat,
affecting millions of people annually, with a significant burden in Asian
countries. Bangladesh, where dengue was first documented in the 1960s, has
witnessed an escalation of cases in recent years. The aim of this review is to
provide an overview on dengue covering dengue epidemiology in Bangladesh and
neighboring countries, efficacy of available vaccines, diagnostic tests and
preventive measures.
Materials and Methods: A
narrative review was conducted using the keywords such as dengue in Bangladesh,
dengue in South and Southeast Asia, epidemiology, genomic structure,
transmission, diagnosis, vaccines and prevention. The information and data of
this article were drawn from extensively reviewed scientific journals and
pertinent authoritative sources. The data search was limited from year 2000 to
2023. 
Results: Magnitude of dengue infection in Bangladesh and
neighboring countries was&amp;nbsp;assessed. The usefulness of
diagnostic tests as well as the prospect of available vaccines was reviewed. Control and preventive measures to mitigate spread and transmission of the
disease were also discussed.
Conclusion: Effective prevention and control of dengue needs
coordinated efforts in surveillance, research, control and preventive measures.
This holistic approach is necessary to mitigate detrimental consequences of
dengue on public health and economies worldwide. 
IMC J Med Sci. 2024; 18(1):012. DOI: https://doi.org/10.55010/imcjms.18.012
*Correspondence: M. S. Zaman, Department of Biological
Sciences, Alcorn State University, Lorman, Mississippi, USA. Email: zaman@alcorn.edu; mzaman@southtexascollege.edu
&amp;nbsp;
Introduction
&amp;nbsp;Dengue fever, a
mosquito-borne viral disease, has profound global impacts, affecting millions
of people each year. This disease is transmitted through the bite of
virus-infected mosquitoes, with the primary vectors being female Aedes
aegypti, followed by Aedes albopictus. The virus is characterized by
four antigenically distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 [1].
However, a fifth serotype (DENV-5) was reported in Malaysia in 2013 [2]. 
Although most dengue cases are not fatal, dengue can lead to
severe illness, known as dengue hemorrhagic fever and dengue shock syndrome,
which often require hospitalization and intensive care. Dengue is a prevalent
endemic illness found in more than 100 countries, primarily in tropical and
subtropical regions worldwide [3].The surge in dengue cases strains healthcare
resources in many countries, especially in regions where the disease is endemic. 
Dengue has had a significant and
concerning impact in Bangladesh, with frequent outbreaks causing substantial
public health challenges. The country faces a recurring cycle of dengue
epidemics, especially during the monsoon season when mosquito breeding sites
are abundant. Most dengue cases are not fatal; however, disease outbreaks
strain the healthcare system, with hospitals and clinics overwhelmed by dengue
cases. The demand for medical care often exceeds the available resources,
leading to difficulties in timely diagnosis and treatment. Furthermore, the
economic impact of dengue in Bangladesh is noteworthy, as families often
struggle to meet the healthcare costs associated with the disease [4]. In
Bangladesh and other dengue endemic countries, the outbreak of dengue diverts
resources away from other healthcare priorities, impacting the overall quality
and accessibility of healthcare services. The burden on the healthcare system,
combined with the economic costs of dengue treatment, aggravates the healthcare
crisis. 
The aim of this brief review is to
provide an understanding on dengue epidemiology in Bangladesh and neighboring
countries, efficacy of available vaccines, diagnostic tests and preventive
measures.
&amp;nbsp;
Materials
and methods
The search strategy
for this narrative review included keywords such as “dengue fever”, “dengue
hemorrhagic fever”, “epidemiology”, “genomic structure”, “transmission”,
“diagnosis”, “serologic tests”, “molecular test”, “vaccines”, “dengue in
Bangladesh”, “dengue in South and Southeast Asia”, and
“epidemic”. The search engines included Google Scholar, Pubmed, Scopus,
MEDLINE, CDC, and WHO websites. The data search was limited from 2000 to 2023.
The inclusion criteria were: (1) articles describing the epidemiology, viral
genotypes and serotypes, risk factors, and prevention. The exclusion criteria
were: (1) articles published before 2000; (2) non-English articles; and (3)
articles not having the full text. The researchers independently searched for
articles and performed the quality appraisal for further inclusion in the
review by reading the full text of the articles. 
&amp;nbsp;
Structure of dengue
virus
Dengue virus is a single-stranded positive-sense enveloped RNA
virus belonging to the Flaviviridae family. The dengue
virus is roughly spherical with a diameter of approximately 50 nanometers. The
viral envelope is a lipid bilayer that encapsulates the nucleocapsid. The
envelope contains E and M proteins across the surface. The virus can assume
different conformations during the maturation and infection stages due to the
flexibility of the envelop proteins. E-protein serves as the primary antigen
causing antibody responses during infection and is essential for the initial
attachment of the virus to the host cells. The amino acid sequence of E-protein
among the different serotypes of DENV bears 60-70% similarity. The core of the
virus is composed of the viral RNA and C proteins [1,5].
The genome of the dengue virus (Figure-1) comprises of a
single-stranded positive-sense RNA. It is composed of ten genes, which are
translated into three structural proteins: (1) capsid C – which plays a crucial role
in encapsulating the viral RNA genome, (2) membrane M having a membrane precursor M (prM)
– which is associated with the organization and maturation of the dengue
virus, and (3) Envelope
E – which is located on the viral surface, is essential for the initial
attachment of the virus to host cells, and seven nonstructural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5 that are involved
in viral replication and assembly processes [1,5].
&amp;nbsp;
&amp;nbsp;
Figure-1: Genome structure of dengue virus [1].
&amp;nbsp;
&amp;nbsp;
Epidemiology
of dengue infection
Dengue is a viral infection transmitted
to humans through the bites of infected mosquitoes, predominantly in tropical
and subtropical regions worldwide, especially in urban and semi-urban
environments. The primary vectors responsible for transmitting dengue to humans
are Aedes aegypti mosquitoes and, to a lesser extent, Aedes
albopictus. Dengue virus is comprised of four distinct serotypes (DENV-1,
DENV-2, DENV-3, DENV-4), and individuals are susceptible to infection by any of
these serotypes. Infection with a specific serotype confers lasting immunity
against that serotype but does not protect from the others. Subsequent
infections may increase the risk of developing severe dengue.
Dengue is a prevalent endemic illness found
in more than 100 countries, primarily in tropical and subtropical regions
worldwide, causing 20,000 to 25,000 deaths annually, mostly in children [3].
Approximately 390 million cases of dengue virus infections are reported
annually across 128 countries, with Asian countries accounting for 70% of these
infections. Out of the total 390 million cases, approximately 96 million are
classified as clinical cases [3]. Age-standardized
incidence rate (ASR) of dengue increased from 1990 to 2011 with a subsequent
decrease per year from 2011 to 2019 [6]. The greatest risk for contracting
dengue infection is in the Indian subcontinent; Southern China; Southeast Asia;
Taiwan; the Pacific Islands; Mexico; Africa; the Caribbean (except for the
Cayman Islands or Cuba); Central and South America, (except for Paraguay,
Chile, and Argentina); Hawaii; areas along the Texas-Mexico border; and Key
West, Florida. 
&amp;nbsp;
Dengue in Bangladesh and neighboring countries
Bangladesh has a subtropical monsoon
climate characterized by wide seasonal variations in rainfall. A warm and humid
climate and stagnant rainwater create favorable breeding grounds for
mosquitoes. This provides a suitable environment for the Aedes mosquitoes,
the primary vectors for dengue. Furthermore, rapid urbanization in Bangladesh
has led to densely populated cities, which provide ample breeding sites for Aedes
mosquitoes in water containers, discarded tires, various other containers, and
ditches that collect rainwater.In Bangladesh, dengue was initially documented in the
1960s and was colloquially referred to as &quot;Dacca fever&quot; [7].The
abundance of the Aedes aegypti mosquito vector and its urban
transmission cycles has established dengue as an endemic disease in Bangladesh.
According to multiple sources, several epidemics of dengue fever affected
Bangladesh in recent years – two major epidemics occurred in 2019 and 2023 [7-11].
The 2019 dengue epidemic had 101,354 confirmed cases and 164 deaths, with a
case-fatality rate (CFR) of 0.16%, whereas the country witnessed the most
devastating epidemic in 2023, which resulted in 320,945confirmed dengue cases
and 1701 deaths (CFR, 0.53%), as reported by the Bangladesh Directorate General of Health Services [11]. Table-1
shows the number of dengue cases,
deaths and case fatality rate in Bangladesh from 2016 to 2023.&amp;nbsp;   
&amp;nbsp;
&amp;nbsp;Table-1: Number
of dengue cases and deaths in Bangladesh from 2016 to 2023 [7-11].
&amp;nbsp;
&amp;nbsp;
The dengue cases were reported from all the 64 districts
of Bangladesh, with a higher number of cases in males than females (62% vs.
58%, respectively). However, the overall CFR was higher in females than in
males (0.72% vs. 0.32%, respectively). Adults aged 30 years and older accounted
for 38% of cases and 64% of all deaths in 2023. In contrast, a previous study
of an outbreak in 2022 had a total of 62,382 cases and 281 fatalities, with a
CFR of 0.45%. Dhaka and Chittagong were the hardest hit cities in the country
[7-11]. An earlier cross-sectional survey of 1,176 households in 2019 reported
a higher prevalence of dengue among adults aged 19 to 50 years and in females
[7-9]. Although DENV3 was detected more frequently in recent past outbreaks,
DENV2 was the predominant serotype isolated during this outbreak [9].The
distribution of dengue cases and deaths by location in Bangladesh is shown in
Figure-2 [11]
&amp;nbsp;
&amp;nbsp;
Figure-2: Distribution of confirmed dengue
cases and number of dengue-related deaths by location in Bangladesh in 2023 [11].
&amp;nbsp;
According to the report compiled by National Center for
Vector Borne Diseases Control in India [12], from January 2018 to September
2023, among the 28 states and 8 Union territories, the most dengue hit places
(with number of dengue cases) in 2023 were: Kerala (9779), Karnataka (9185),
Maharashtra (8496), Odisha (6563), Uttar Pradesh (5742), and Assam (5604). Data
from West Bengal was not reported in the previously mentioned source. However,
Hindustan Times (a daily newspaper in India) reported the highest number of
dengue cases (over 76,000) in West Bengal as of November 1, 2023 [13].
According to World Health Organization (WHO), dengue
cases in Southeast Asia regions increased by 46% (from 451,442 to 658,301) and
deaths decreased by 2% (from 1,584 to 1.555) from 2015 to 2019. Tian and
colleagues reviewed dengue incidence and used disability-adjusted life years
(DALY) to measure the disease burden of dengue fever in the endemic countries
in Southeast Asia [15]. The age-standardized rate increased by 33% from 557.15 (95% CI 243.32 to
1212.53) per 100,000 in 1990 to 740.4 (95% CI 478.2 to 1323.1) per 100,000 in
2019 in these countries. Six countries including Bangladesh,
India, Indonesia, Myanmar, Sri Lanka, and Thailand are among the high-endemic
countries in the world [14]. An increase of dengue mosquito vector and viruses
due to increased population density, increased migration in urban areas,
inadequate water supply, poor waste management systems, and global warming are
among the reasons for the dengue upsurge over time.
&amp;nbsp;
Transmission
Dengue
transmission is primarily carried out by two mosquito species, Aedes aegypti
and Aedes albopictus. However, Aedes aegypti plays a primary role
because this mosquito species can adapt to various environments. They breed in
water collected in small containers, flowerpots, tires, and any stagnant water,
adapting to all types of surroundings. Dengue
transmission pathways involve a complex interaction involving the virus,
mosquitoes (vectors), and humans (hosts). The process is outlined in Figure-3.&amp;nbsp;
&amp;nbsp;
&amp;nbsp;
Figure-3: The pathways involved in the transmission
of dengue virus [16-18].
&amp;nbsp;
Apart from symptomatic dengue cases,
asymptomatic infections play a significant role in the transmission of dengue
infection. Estimated overall global prevalence of asymptomatic dengue infection
has been reported as 59.3% with 65.5% and 30.8% during outbreaks and
non-outbreak periods respectively [19-21]. However, WHO reports that around 80%
of dengue cases do not show any symptom [3]. Therefore, detection of
asymptomatic dengue is crucial to prevent spread of dengue in a community. 
&amp;nbsp;
Diagnostic tests
The primary focus in diagnosing dengue should be on the detection
of the virus or the viral components. During the acute stage of the infection,
diagnosis can be made by detection of the virus, or its nucleic acids or
antigens. Typically, within the first 4 to 5 days of the onset of the disease,
the virus can be detected in plasma, blood cells, and various tissues [22]. For patients seeking medical attention within the five
days of the onset of fever, diagnostic assessment should include rRT-PCR
(testing for viral RNA) or NS1 antigen test. NS1
antigen test detects the non-structural protein NS1 of dengue virus. This
protein is secreted into the blood during dengue infection. NS1 has shown to produce positive results for up to
12 days after the onset of fever. In addition, Immunoglobulin M (IgM) antibodies to
viral antigen also start to appear around 3-7 days following the onset of
symptoms. 
During the post-acute stage, serology is the method of choice for
diagnosis which detects IgM or IgG antibodies. First-time (primary) dengue virus infections typically show a stronger
IgM response; however, subsequent (secondary) infections show a weaker IgM
response but a stronger IgG response [22]. For patients with more than one week
after the onset of fever, IgM detection is the most effective diagnostic method
[23]. IgM antibodies become detectable 3 to 7 days following infection and
could remain detectable for 6 months or longer [23]. It takes approximately 5 to 7 days
following the onset of symptoms for immunoglobulin G (IgG) antibodies to become
detectable, and these levels may remain elevated for years [22]. 
&amp;nbsp;In
2023, Luvira et al reported serum concentration by the ultrafiltration method
as a simple and applicable technique to improve the diagnostic sensitivity and
specificity of NS1 antigen test [24]. Dengue NS1 detection by enzyme-linked
immunosorbent assay (ELISA) had the highest sensitivity of 82.4% (and 94.3%
specificity), while NS1 by rapid diagnostic test (RDT) had 76.5% sensitivity,
when compared with the viral detection by polymerase chain reaction (PCR).
Serum concentrated three times with the ultrafiltration method using a 10 kDa
molecular weight cut-off membrane increased the sensitivity of RDT-NS1
detection from 76.5% to 80.4%, with 100% specificity. Combining NS1 and IgM
detection, the concentration method further increased the RDT sensitivity to
82.4% with 100% specificity.
&amp;nbsp;
Prevention
Mosquito control: Mosquito control efforts rely on eradicating mosquito
breeding sites, as mosquitoes lay their eggs in stagnant water. Regular
inspections and removal of potential breeding sites like discarded tires,
flowerpots, containers, and puddles where water accumulates are essential. Furthermore, the use of larvicides can help
eliminate mosquito larvae in stagnant water, while using mosquito screens or
nets can prevent mosquitoes from infiltrating living spaces. In addition to
various mosquito control measures, studies indicate that Bacillus
thuringiensis, often referred to as “Bt,” can serve as a successful
larvicide against mosquito larvae. The Sterile Insect Technique (SIT) has
proven effective in numerous nations for managing mosquito populations,
although its ecological consequences are not clearly understood [25].
Furthermore, scientists are exploring the potential of Wolbachia, a
bacterium that naturally occurs in mosquitoes and various insects, as a means
to manage mosquito populations. The concept involves releasing male mosquitoes
containing Wolbachia into selected
regions. These Wolbachia-infected
male mosquitoes subsequently mate with indigenous wild female mosquitoes. This
mating process results in unhatched eggs, consequently decreasing the
population of Aedes aegypti mosquitoes, which are the primary carriers
of the dengue virus [26].
Protective measures: Wearing long-sleeved shirts, long pants, socks, and shoes in areas where
mosquito activity is high, especially during dawn and dusk, could protect from
mosquito bites. Using mosquito repellent on exposed skin and clothing, seeking
shelters in screened areas, and using mosquito nets could also provide
protection against mosquito bites.
Community and public health initiatives: Identifying and cleaning up potential mosquito breeding sites in the
community, campaigning and raising awareness about dengue prevention and control,
educating students about dengue prevention through school programs, and
implementing travel restrictions to and from dengue-infected areas, could play
a significant role in dengue prevention. 
Dengue Vaccines: There are several challenges in developing
an effective dengue vaccine – simply because of the complexities of formulating
a tetravalent vaccine, and in conducting an efficacy trial against all four
serotypes. At least seven DENV vaccines have undergone different phases of
clinical trials; they include: (1) tetravalent, live-attenuated vaccines, (2)
chimeric live attenuated vaccines, (3) inactivated vaccines, (4) subunit
vaccines, and (5) nucleic acid-based vaccines. However, only three of them
(Dengvaxia®, Odenga or TAK-003, and TV003/005) have showed promising
results in several studies [27-29]. Table-2
summarizes the three vaccines with promising efficacy against dengue infection.

&amp;nbsp;
Table-2: Comparison of
available vaccines for dengue [27-29]
&amp;nbsp;
&amp;nbsp;
Dengvaxia® is a tetravalent live-attenuated dengue vaccine (LATV),
which received authorization in 2022 for use in children, aged 9 to 16 with a
confirmed history of dengue infection and living in dengue-endemic regions [27].
This vaccine is only for individuals with prior dengue infections. If given to
individuals without a previous infection who later contract the virus, the risk
of severe dengue is high. The vaccine’s effectiveness is achieved through a
three-dose regimen, with each dose spaced 6 months apart. Until now, among all the
available vaccines, Dengvaxia protects children from dengue illness,
hospitalizations, and severe dengue 8 out of 10 times (80%) in children who had
dengue before vaccination. The vaccine protects against all four dengue virus
serotypes [29].
Qdenga (TAK-003), a dengue
tetravalent vaccine, is recommended by the World Health
Organization (WHO) for children aged 6 to 16, irrespective of their previous
dengue infection history. Therefore, a laboratory-confirmed dengue infection is
not a prerequisite. This vaccine is administered as a two-shot series with a
3-month interval [29].
TV003/TV005 is a tetravalent live-attenuated dengue
vaccine. It is produced by the National
Institute of Allergy and Infectious Diseases (NIAID) of the United States and
the Butantan Institute in Brazil. Of the five
LATV formulations that were evaluated, TV003 and TV005 induced the most
balanced neutralizing antibody responses [29]. TV005 is an improved version of
TV003; it significantly increases seroconversion and antibody titers against
DENV2. 
A recent clinical trial of TV005 focusing on safety and
immunogenicity has been successfully carried out in Bangladesh [30]. The study demonstrated that by 180 days post
vaccination, 83%, 99%, 96%, 87% vaccine recipient were found seropositive to
DENV1, DENV2, DENV3 and DENV4 respectively. Antibody titers to all serotypes
remained stable in 63-86% adults after 3 years of follow-up. However, the
antibody titters declined in individuals without past exposure to dengue by 3
years. 
However, it&#039;s essential to recognize
that the dengue vaccine can have specific side effects, including soreness,
itching, headaches, fatigue, and general discomfort. In rare instances,
individuals may experience fainting after vaccination, and there is a minimal
risk of a severe allergic reaction triggered by the vaccine [30]. It is
advisable to consult with a healthcare professional before considering
vaccination.
&amp;nbsp;
Discussion
Dengue is an endemic disease in many countries. While
cases can crop up anywhere, they typically occur in tropical and subtropical
regions where rainfall and humidity are high. Dengue fever is primarily
prevalent during the rainy season. There are an estimated 400 million dengue
cases that occur throughout the world each year. Of those, approximately one in
four, or 96 million, results in illness [8,14]. It is considered a significant
public health issue, and its impact is felt worldwide.In
Bangladesh, dengue is an endemic disease that primarily surfaces during the
monsoon season. In recent years dengue infection in Bangladesh has been
significantly high, creating significant pressure on the healthcare system
which is not fully prepared to tackle this added stress. Since the vector
carrying the virus is a mosquito, it is easily comprehendible that the
eradication of mosquito breeding sites would produce significant progress in
dengue prevention and control in Bangladesh. Due to the high population density
and rapid urbanization, the risk of re-infection from dengue remains a
formidable challenge in Bangladesh, and controlling the situation remains a
concern.
The
climatic conditions in Bangladesh are progressively becoming more conducive to
the transmission of dengue and other vector-borne diseases such as malaria and
chikungunya. This change is attributed to factors like excessive rainfall,
water logging, flooding, rising temperatures, and significant alterations in
the country’s traditional seasonal patterns [8].
In
Bangladesh, the dengue situation in 2023 is cause for serious concern, with a significant
increase in both the number of dengue cases and related fatalities compared to
the past five years. The dengue virus has affected all 64 districts of
Bangladesh. The surge in dengue cases began in May 2023 and has persisted since
then [9,10,11]. However, because of possibility of under reporting, it is
assumed that the actual figures for both cases and fatalities may be
considerably higher than the reported numbers.
Based
on a survey run by the Directorate General of Health Services (DGHS), in the
earlier part of 2022 (pre-monsoon), there was an increased concentration of Aedes
mosquitoes in Dhaka, exceeding the levels recorded in 2021. Experts in the
Communicable Disease Control (CDC) unit of the DGHS had foreseen a
deteriorating dengue situation in Dhaka city for this year unless proactive
measures were implemented. A follow-up survey, (monsoon) produced in September,
indicated that the mosquito population in Dhaka city doubled compared to the
pre-monsoon assessment [[9,10,11]. Therefore, this current outbreak could have
been predicted. The reports from the CDC should have been treated with utmost
seriousness, and prompt, well-targeted measures from the relevant agencies
could have played a crucial role in alleviating the ongoing crisis.
The
fundamental aspect of dengue prevention is safeguarding the population from
dengue virus transmission. There is no alternative to individual and social
awareness and governmental engagement for dengue control. Mosquito and larva
eradication efforts must be undertaken at both the government and private
levels. The examples of school, college, and community-based voluntary
initiatives are not new in Bangladesh. Social and political organizations must
take a proactive role. Additionally, using mosquito nets and mosquito repellent
creams at home could provide essential avoidance from mosquitoes.
This
review is limited by the fact that a literature review of similar nature is
prone to bias, which could be reduced by a systematic review. Since this study
did not follow a systematic review methodology, the search strategies did not
warrant a comprehensive review. Further, this study included data for about 22
years, primarily using the outbreaks reported from Bangladesh. In addition, the
review did not use a systematic method of reducing the risk of bias assessment
by meta-analysis of the data.
&amp;nbsp;
Conclusions
Dengue
prevention and control in Bangladesh and other dengue endemic countries of the
region require a dedicated multi-pronged approach involving individual, social,
and government efforts. Additionally, the global impacts of dengue also highlight
the need for coordinated efforts in surveillance, research, and preventive
measures to combat the spread of the disease and its detrimental consequences
on public health and economies worldwide.
&amp;nbsp;
Competing interest
No competing interest/conflict of
interest.
&amp;nbsp;
References
1.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Aryal,
S. (Editor). Dengue and dengue virus – An overview. &amp;nbsp;Microbe Notes. 2021. Available at: https://microbenotes.com/dengue/ [Accessed 12 December 2023].
2.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Mustafa MS,
Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus
(DENV-5): A new public health dilemma in dengue&amp;nbsp;control. Med J Armed
Forces India. 2015; 71(1):
67-70. doi: 10.1016/j.mjafi.2014.09.011.
3.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; World Health Organization (21 December
2023). Disease Outbreak News; Dengue – Global situation Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498.
[Accessed 30 &amp;nbsp;December 2023]
4.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Sarker AR, Paul S, Zohara F, Hossain Z, Zabeen
I, Chowdhury SMZI, et al. &amp;nbsp;Economic
burden of dengue in urban Bangladesh: A societal perspective. PLoS Negl Trop Dis. 2023; 17(12): e0011820.
doi:10.1371/journal.pntd.0011820 
5.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Beasley DWC, Barrett ADT. The Infectious Agent. In:
Pasvol G, Hoffman SL, editors. Dengue. Vol. 5. Covent Garden, London, UK: Imperial College
Press; 2008. p. 29–73.
6.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Du M, Jing W, Liu M, Liu J. The Global
Trends and Regional Differences in Incidence of Dengue Infection from 1990 to
2019: An Analysis from the Global Burden of Disease Study 2019. Infect Dis
Ther. 2021; 10(3): 1625-1643.
doi:10.1007/s40121-021-00470-2.
7.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; World Health Organization (11 August 2023).
Disease Outbreak News; Dengue in Bangladesh. Available at:&amp;nbsp;https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON481.
8.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; World Health Organization (17 March 2023).
Dengue and severe dengue. Available at: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue [Accessed 13
December 2023].
9.&amp;nbsp; &amp;nbsp; &amp;nbsp;UNICEF.
Bangladesh Dengue Outbreak. Situation Report #6
15th December 2023. Available at: https://www.unicef.org/media/150136/file/Bangladesh%20Humanitarian%20Situation%20Report%20No.%206%20(Dengue%20Outbreak)%2015%20December%202023.pdf [Accessed 30 December 2023]  
10.&amp;nbsp; Bhowmik KK, Ferdous
J, Baral PK, Islam MS. Recent outbreak of dengue in Bangladesh: A threat to
public health. Health Sci Rep. 2023; 6(4): e1210. doi: 10.1002/hsr2.1210.
11.&amp;nbsp; Directorate General Health Services (DGHS),
Bangladesh. Bangladesh 2023 dengue outbreak. &amp;nbsp;ACAPS Briefing Notes. 26 September 2023.
Available at: https://www.acaps.org/fileadmin/Data_Product/Main_media/20230926_ACAPS_briefing_note_Bangladesh_2023_dengue_outbreak.pdf [accessed 30 December 2023].
12.&amp;nbsp; National Center for Vector Borne Diseases
Control, Directorate General of Health Services, Ministry of Health &amp;amp;
Family Welfare, Government of India. Dengue Situation in India: Dengue cases and
deaths in the country since 2018. Available at: https://ncvbdc.mohfw.gov.in/index4.php?lang=1&amp;amp;level=0&amp;amp;linkid=431&amp;amp;lid=3715[Accessed
14 December 2023].
13.&amp;nbsp; Hindustan Times (December 14, 2023). West
Bengal records over 76,000 dengue cases in 2023, nearly 10,000 more than 2022.
Available at: https://www.hindustantimes.com/cities/kolkata-news/west-bengal-records-over-76-000-dengue-cases-in-2023-nearly-10-000-more-than-2022-101698810081173.html[Accessed
14 December 2023].
14.&amp;nbsp; World Health Organization. Health topics:
Dengue in South-East Asia. Available at: https://www.who.int/southeastasia/health-topics/dengue-and-severe-dengue
[Accessed 14 December 2023].
15.&amp;nbsp; Tian N, Zheng JX, Guo ZY, et al. Dengue
Incidence Trends and Its Burden in Major Endemic Regions from 1990 to 2019. Trop
Med Infect Dis. 2022; 7(8): 180.
doi:10.3390/tropicalmed7080180
16.&amp;nbsp; Kraemer MU, Sinka
ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global
distribution of the arbovirus vectors&amp;nbsp;Aedes aegypti&amp;nbsp;and&amp;nbsp;Ae.
albopictus. Elife. 2015;&amp;nbsp;4: e08347. doi: 10.7554/eLife.08347.
17.&amp;nbsp; Mukherjee D, Das S,
Begum F, Mal S, Ray U. The mosquito immune system and the life of dengue virus:
What we know and do not know. Pathogens.
2019; 8(2):77. doi: 10.3390/pathogens8020077. 
18.&amp;nbsp; Novelo M, Hall MD,
Pak D, Young PR, Holmes EC, McGraw EA. Intra-host growth kinetics of dengue
virus in the mosquito Aedes aegypti. PLoS Pathog. 2019; 15(12): e1008218. doi:
10.1371/journal.ppat.1008218. 
&amp;nbsp;19. Asish
PR, Dasgupta S, Rachel G, Bagepally BS, Girish Kumar CP. Global prevalence of
asymptomatic dengue infections - a systematic review and meta-analysis. Int
J Infect Dis. 2023; 134: 292-298.
doi:10.1016/j.ijid.2023.07.010
20.&amp;nbsp; Duong V, Lambrechts L, Paul RE, Ly S, Lay RS,
Long KC, et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc
Natl Acad Sci U S A. 2015; 112(47):
14688-14693. doi:10.1073/pnas.1508114112.
21.&amp;nbsp; ten Bosch QA, Clapham HE, Lambrechts L, Duong
V, Buchy P, Althouse BM, et al. Contributions from the silent majority dominate
dengue virus transmission. PLoS Pathog. 2018; 14(5): e1006965. doi:10.1371/journal.ppat.1006965. 
22.&amp;nbsp; Dengue: Guidelines for Diagnosis, Treatment,
Prevention and Control: New Edition. Geneva: World Health Organization; 2009. 
&amp;nbsp;23. CDC
(3 May 2019). Testing for dengue virus. Available at: https://www.cdc.gov/dengue/healthcare-providers/testing/index.html [Accessed 13
December 2023].
24.&amp;nbsp; Luvira V, Thawornkuno C, Lawpoolsri S, Thippornchai
N, Duangdee C, Ngamprasertchai T, et al. Diagnostic Performance of Dengue NS1
and Antibodies by Serum Concentration Technique. Trop Med Infect Dis. 2023; 14; 8(2):
117. doi: 10.3390/tropicalmed8020117.
25.&amp;nbsp; World Health
Organization (14 November 2019). Mosquito sterilization offers new opportunity
to control chikungunya, dengue, and Zika. Available at: https://www.who.int/news/item/14-11-2019-mosquito-sterilization-offers-new-opportunity-to-control-chikungunya-dengue-and-zika#:~:text=A%20technique%20that%20sterilizes%20male,form%20of%20insect%20birth%20control [Accessed 13 December 2023].
26.&amp;nbsp; CDC (15 July 2022). Mosquitoes with Wolbachia
for reducing numbers of Aedes aegypti mosquitoes. Available at: https://www.cdc.gov/mosquitoes/mosquito-control/community/emerging-methods/wolbachia.html
[Accessed 13 December 2023].
27.&amp;nbsp; Torres-Flores JM,
Reyes-Sandoval A, Salazar MI. Dengue Vaccines: An Update. Bio Drugs. 2022; 36(3): 325-336.
doi: 10.1007/s40259-022-00531-z.&amp;nbsp;
28.&amp;nbsp; Chen Y, Huang A, Sui Y, Tong X, Yu F. Progress
and development of three types of live attenuated vaccines for dengue fever. Highl Sci Eng Tech 2022; 8: 497-504. doi: doi.org/10.54097/hset.v8i.1204 
29.&amp;nbsp; CDC. Dengue Vaccination: What Everyone Should
Know. Center for Disease Control and Prevention. 2023. Available at: https://www.cdc.gov/vaccines/vpd/dengue/public/index.html [Accessed 12 December 2023].
30.&amp;nbsp; Walsh MR, Alam MS, Pierce KK, Carmolli M, Alam
M, Dickson DM, et
al. Safety and durable immunogenicity of the TV005 tetravalent
dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh:
a randomised, controlled trial. Lancet
Infect Dis. 2023: S1473-3099(23)00520-0. doi:
10.1016/S1473-3099(23)00520-0.
&amp;nbsp;
&amp;nbsp;
Cite this article as:

Zaman MS, Mitra AK. Dengue in Bangladesh and neighboring countries: an overview of epidemiology, transmission, control,&amp;nbsp;and prevention. IMC J Med
Sci. 2024; 18(1):012. &amp;nbsp;DOI: https://doi.org/10.55010/imcjms.18.012</description>

            </item>
            
    <copyright>2026 Ibrahim Medical College. All rights reserved.</copyright>
</channel>
</rss>
